<DOC>
	<DOCNO>NCT01893255</DOCNO>
	<brief_summary>This observational study evaluate use efficacy RoActemra/Actemra ( tocilizumab ) monotherapy routine clinical practice patient rheumatoid arthritis . Eligible patient initiated RoActemra/Actemra treatment accord approve label follow 6 month .</brief_summary>
	<brief_title>A Non-Interventional Study Patients With Rheumatoid Arthritis Who Are Treated With RoActemra/Actemra ( Tocilizumab )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Adult patient , &gt; /= 18 year age Moderate severe rheumatoid arthritis accord revise ( 1987 ) ACR criterion Patients treat physician make decision commence RoActemra/Actemra treatment accordance local label ; include patient receive RoActemra/Actemra treatment within 8 week prior enrolment visit Patients reason take methotrexate treat physician make decision prescribe RoActemra/Actemra monotherapy Patients previously TNF inhibitor monotherapy , treat physician make decision prescribe RoActemra/Actemra monotherapy Concomitant treatment corticosteroid ( orally intraarticularly ) and/or NSAIDs allow Patients receive RoActemra/Actemra 8 week prior enrolment visit Patients previously receive RoActemra/Actemra clinical trial compassionate use Patients receive concomitant DMARD treatment rheumatoid arthritis ( e.g . hydroxychloroquine , sulfasalazine , methotrexate , leflunomide , gold compound , cyclosporine ) Patients received treatment investigational agent within 4 week ( 5 halflives investigational agent , whichever long ) start treatment RoActemra/Actemra Patients history autoimmune disease joint inflammatory disease rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>